Armando Orlandi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.

Journal: Breast (Edinburgh, Scotland)

Published: February 22, 2026

The curious incident of the T-DXd alone arm at (DESTINY-Breast) 11 o'clock.

The curious incident of the T-DXd alone arm at (DESTINY-Breast) 11 o'clock.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 31, 2026

The Curious Incident of the T-DXd Arm Killed at (DESTINY-Breast) Eleven O'Clock: Statistical Concerns.

The Curious Incident of the T-DXd Arm Killed at (DESTINY-Breast) Eleven O'Clock: Statistical Concerns.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 31, 2026

When Is Enough Enough? Personalized Decision Making in Long-Term Cancer Care.

When Is Enough Enough? Personalized Decision Making in Long-Term Cancer Care.

Journal: JCO oncology practice

Published: November 14, 2025

Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort.

Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort.

Journal: Cancers

Published: November 14, 2025

Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach.

Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach.

Journal: Breast (Edinburgh, Scotland)

Published: November 13, 2025

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project.

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project.

Journal: Healthcare (Basel, Switzerland)

Published: September 15, 2025

RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.

RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.

Journal: Journal of the National Cancer Institute

Published: September 02, 2025

Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.

Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.

Journal: Journal of personalized medicine

Published: August 31, 2025

FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation?

FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation?

Journal: Breast (Edinburgh, Scotland)

Published: July 07, 2025

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Journal: Current oncology (Toronto, Ont.)

Published: June 30, 2025

Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.

Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.

Journal: Future oncology (London, England)

Published: June 14, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026